PropertyValue
?:abstract
  • The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS‐CoV‐2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS‐CoV‐2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti‐SARS‐CoV‐2 compounds in vitro Support Protocol: SARS‐CoV‐2 propagation
?:creator
?:doi
?:doi
  • 10.1002/cpmc.108
?:journal
  • Curr_Protoc_Microbiol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/caa91a7e09a2d3b7cf7bd719e86deb186f748ccd.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7361222.xml.json
?:pmcid
?:pmid
?:pmid
  • 32585083.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
?:type
?:year
  • 2020-06-25

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/byx3ts1d>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/byx3ts1d>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all